A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Summary

The purpose of this first-time-in-human (FTiH) study is to assess the reactogenicity, safety and immunogenicity of four different dose levels of an experimental herpes simplex virus type 2 (HSV-2) vaccine, when administered intramuscularly (IM) on a 0, 2-month schedule to healthy participants aged 18-40 years.

Timeline

Start

2021-03-02

Primary completion

2021-05-26

Completion

2021-05-26

Outcome

Outcome not reported

Stopped: “To enable development of an enhanced version of the vaccine”

Drugs

Indications